UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 1, 2005
PERRIGO COMPANY
---------------
(Exact name of registrant as specified in its charter)
MICHIGAN 0-19725 38-2799573
--------------- ------------ -------------------
(State or other (Commission (IRS Employer
Jurisdiction of File Number) Identification No.)
Incorporation)
515 Eastern Avenue, Allegan, Michigan 49010
------------------------------------------ ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (269) 673-8451
--------------
Not Applicable
--------------------------------------------------------------------------------
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS
Product Recall
The Company has initiated a voluntary retail-level recall of all lots of
concentrated infants' drops packaged with a dosing syringe.
The products are being recalled because the oral dosing syringe enclosed with
these products is not marked so as to accurately measure doses less than 1.6 mL
when prescribed by physicians for infants younger than 2 years and weighing less
than 24 pounds. Until recently these products were provided with a dropper, not
the oral dosing syringe, and the dropper had two markings on it ("0.4 mL" and
"0.8 mL"). The single mark on the current syringe along with the changeover from
the dropper to this syringe has caused some confusion among consumers and
health-care professionals and may lead to improper dosing.
The value of the Company's on-hand inventories and the cost of return and
disposal are estimated to be approximately $2 million and will be recorded in
the fiscal 2005 fourth quarter ending June 25, 2005.
Certain statements in this 8-K are forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended, and are
subject to the safe harbor created thereby. These statements relate to future
events or the Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, levels of activity, performance or achievements of the Company or its
industry to be materially different from those expressed or implied by any
forward-looking statements. In some cases, forward-looking statements can be
identified by terminology such as "may," "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or other comparable terminology. Please see the "Cautionary Note
Regarding Forward-Looking Statements" on pages 27 - 33 of the Company's Form
10-K for the year ended June 26, 2004 for a discussion of certain important
factors that relate to forward-looking statements contained in this press
release. Although the Company believes that the expectations reflected in these
forward-looking statements are reasonable, it can give no assurance that such
expectations will prove to be correct. Unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PERRIGO COMPANY
(Registrant)
By: /s/ Douglas R. Schrank
----------------------
Dated: August 1, 2005 Douglas R. Schrank
Executive Vice President and
Chief Financial Officer
(Principal Accounting and
Financial Officer)